Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Cancer Research|May 15, 1989
Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and organ toxicityR W Kozak, A Raubitschek, S Mirzadeh, et al.
Radiation Research|May 15, 2002
Vascular-targeted radioimmunotherapy with the alpha-particle emitter 211AtS J Kennel, S Mirzadeh, W C Eckelman, et al.
Nanoscale|April 24, 2020
Quantitative encapsulation and retention of 227Th and decay daughters in core-shell lanthanum phosphate nanoparticlesM Toro-González, A N Dame, C M Foster, et al.
Nuclear Medicine and Biology|September 3, 1999
Comparison of 225actinium chelates: tissue distribution and radiotoxicityI A Davis, K A Glowienka, R A Boll, et al.
Transplantation|November 1, 1990
Use of yttrium-90-labeled anti-Tac antibody in primate xenograft transplantationM M Cooper, R C Robbins, C K Goldman, et al.
Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine|March 31, 1998
Reactor-produced radioisotopes from ORNL for bone pain palliationF F Knapp, S Mirzadeh, A L Beets, et al.
Radiation Research|March 12, 1999
Radiotoxicity of bismuth-213 bound to membranes of monolayer and spheroid cultures of tumor cellsS J Kennel, M Stabin, J C Roeske, et al.
Acta Neurologica Belgica|July 4, 2024
Atypical presentations in an RTD patient and report of novel SLC52A3 and SLC52A2 mutationsDonya Sabeghi, Kolsoum InanlooRahatloo, Hanieh S Mirzadeh, et al.
International Journal of Radiation Oncology, Biology, Physics|March 1, 1984
211At radiocolloid therapy: further observations and comparison with radiocolloids of 32P, 165Dy, and 90YW D Bloomer, W H McLaughlin, R M Lambrecht, et al.
Nuclear Medicine Communications|December 16, 1998
Rhenium-188 microspheres: a new radiation synovectomy agentS J Wang, W Y Lin, M N Chen, et al.
Pageof 5